Compare Dyne Therapeutics Inc. Common Stock (DYN) vs J B Hunt Transport Services Inc (JBHT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs J B Hunt Transport Services Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while J B Hunt Transport Services Inc trades at $230.52 (market cap $21.52B). The key difference: J B Hunt Transport Services Inc is far larger — about 7.5× Dyne Therapeutics Inc. Common Stock's market cap, and J B Hunt Transport Services Inc pays a 0.79% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and J B Hunt Transport Services Inc for 46 Days on average.
| DYN | JBHT | |
|---|---|---|
Market Cap | $2.86B | $21.52B |
Volume | 3,341,579 | 994,790 |
Sector | Health | Industrials |
52-Week High | $26.78 | $298.41 |
52-Week Low | $14.60 | $138.83 |
Typical Hold Time | 0 Days | 46 Days |
Enterprise Value | $2.18B | $22.66B |
Dividend Yield | — | 0.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
JBHT trades at $232.16, up 1.69% today, with a bearish technical signal but strong fundamental profitability. Recent earnings have consistently beaten expectations, with Q3 2026 results due October 15, 2026. The company maintains solid margins, with a net income margin of 5.31% and ROE of 18.45%, though revenue has declined from 2022 peaks. Cash flow from operations remains healthy at $1.68 billion for 2025.
Analyst consensus is bullish with a $287.93 price target, but near-term risks include rising costs pressuring Q3 earnings and multiple law firm investigations into potential securities claims. The stock offers upside if execution improves, but investors face headwinds from fuel expenses and legal overhangs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About J B Hunt Transport Services Inc
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →
